224 related articles for article (PubMed ID: 36697072)
21. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab After Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data.
Jang JY; Song SY; Shin YS; Kim HU; Choi EK; Kim SW; Lee JC; Lee DH; Choi CM; Yoon S; Kim SS
Cancer Res Treat; 2024 Jan; ():. PubMed ID: 38228082
[TBL] [Abstract][Full Text] [Related]
22. Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).
Nakamichi S; Kubota K; Misumi T; Kondo T; Murakami S; Shiraishi Y; Imai H; Harada D; Isobe K; Itani H; Takata S; Wakui H; Misumi Y; Ikeda S; Asao T; Furuya N; Hosokawa S; Kobayashi Y; Takiguchi Y; Okamoto H
Clin Cancer Res; 2024 Mar; 30(6):1104-1110. PubMed ID: 38165684
[TBL] [Abstract][Full Text] [Related]
23. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
24. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H
BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838
[TBL] [Abstract][Full Text] [Related]
25. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
Yamada T; Goto Y; Tanaka H; Kimura H; Minato K; Gyotoku H; Honda T; Watanabe S; Morimoto K; Kiyomi F; Uchino J; Takayama K
Eur J Cancer; 2023 Dec; 195():113373. PubMed ID: 37890349
[TBL] [Abstract][Full Text] [Related]
27. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.
Mehra R; Yong C; Seal B; van Keep M; Raad A; Zhang Y
J Natl Compr Canc Netw; 2021 Feb; 19(2):153-162. PubMed ID: 33545688
[TBL] [Abstract][Full Text] [Related]
29. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer.
Saito S; Abe T; Kobayashi N; Aoshika T; Ryuno Y; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Clin Transl Radiat Oncol; 2020 Jul; 23():85-88. PubMed ID: 32529055
[TBL] [Abstract][Full Text] [Related]
30. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
[TBL] [Abstract][Full Text] [Related]
31. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.
Kishi N; Matsuo Y; Shintani T; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Ohtsu S; Katagiri T; Narabayashi M; Fujishiro S; Iizuka Y; Ozasa H; Hirai T; Mizowaki T;
J Radiat Res; 2023 Jan; 64(1):142-153. PubMed ID: 36149029
[TBL] [Abstract][Full Text] [Related]
32. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study.
Takeda Y; Kusaba Y; Tsukita Y; Uemura Y; Miyauchi E; Yamamoto T; Mayahara H; Hata A; Nakayama H; Tanaka S; Uchida J; Usui K; Toyoda T; Tamiya M; Morimoto M; Oya Y; Kodaira T; Jingu K; Sugiura H
Clin Transl Radiat Oncol; 2022 Nov; 37():57-63. PubMed ID: 36065360
[TBL] [Abstract][Full Text] [Related]
33. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
34. Five-year survival rate analysis: the combination of fortnightly-administration of endostar and concurrent chemoradiotherapy versus concurrent chemoradiotherapy in the treatment of inoperable locally advanced non-small cell lung cancer.
Ma H; Peng F; Xu Y; Bao Y; Hu X; Wang J; Fang M; Kong Y; Dong B; Chen M
Ann Palliat Med; 2021 Jul; 10(7):7560-7570. PubMed ID: 34353044
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A; Ono A; Wakuda K; Kawabata T; Yabe M; Miyawaki T; Miyawaki E; Kodama H; Nishioka N; Mamesaya N; Kobayashi H; Omori S; Kenmotsu H; Naito T; Murakami H; Harada H; Takahashi T
Invest New Drugs; 2022 Apr; 40(2):403-410. PubMed ID: 34633575
[TBL] [Abstract][Full Text] [Related]
36. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
[TBL] [Abstract][Full Text] [Related]
37. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
[TBL] [Abstract][Full Text] [Related]
38. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Noh JM; Kim JM; Ahn YC; Pyo H; Kim B; Oh D; Ju SG; Kim JS; Shin JS; Hong CS; Park H; Lee E
Cancer Res Treat; 2016 Jan; 48(1):106-14. PubMed ID: 25687865
[TBL] [Abstract][Full Text] [Related]
39. Durvalumab after concurrent chemoradiotherapy in a patient with chemotherapy-resistant unresectable stage III non-small cell lung cancer: a case report.
Zhang T; Wu Y; Zheng S; Cheng G; He X; Bi N
Ann Palliat Med; 2020 Jul; 9(4):2375-2380. PubMed ID: 32692219
[TBL] [Abstract][Full Text] [Related]
40. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]